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Non-obstructive coronary artery disease is prevalent in the United States and is 
associated with acute coronary syndrome and heart failure. Despite its prevalence and 
morbidity, no standard therapy exists for non-obstructive coronary artery disease. The 
development of non-obstructive coronary artery disease involves coronary microvascular 
dysfunction, which is primarily driven by endothelial dysfunction. Therefore, exploring 
therapies to improve endothelial function could benefit patients with coronary 
microvascular dysfunction. Ticagrelor is a P2Y12 inhibitor that is used for its anti-
platelet effects and is also thought to improve endothelial function. Therefore, we 
propose to investigate the effects of ticagrelor versus placebo on coronary flow reserve, a 
measure of endothelial function in the coronary blood vessels, via positron emission 
tomography using a randomized controlled trial double-blind approach. Results from our 
study will test the feasibility of ticagrelor as a therapy for coronary microvascular 
dysfunction, a condition that currently lacks any treatment guidelines. 
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Non-obstructive coronary artery disease, or ischemia with no obstructive coronary 
artery disease (INOCA), affects around three million people in the United States and is 
associated with acute coronary syndrome, heart failure, and stroke.1,2 INOCA is defined 
as less than 50 percent stenosis of one or more coronary arteries.1 The development of 
INOCA involves coronary microvascular dysfunction (CMD). CMD has been shown to 
make up about 20 to 60 percent of patients with INOCA.3 The pathophysiology of CMD 
is primary driven by endothelial dysfunction and to a lesser extent arterial remodeling 
and fibrosis, vascular smooth muscle hyperreactivity and hypertrophy, and sympathetic 
nervous system activation.4-6 The vascular endothelium produces nitric oxide and 
prostacyclin which function against sclerosis and thrombosis by inhibiting platelet 
activation .7-9 Conversely, endothelial dysfunction is associated with inflammation, 
vasoconstriction, coagulation, and myocardial ischemia.10 Endothelial dysfunction results 
in decreased coronary artery compliance and low endothelial sheer stress. Low 
endothelial sheer stress increases the risk of forming vulnerable coronary plaques, which 
are plaques that can erode and rupture, causing acute coronary events.11-14 Most fatal 
coronary thrombi are caused by plaque rupture.15,16  
In addition to acute myocardial events, endothelial dysfunction can cause 
myocardial ischemia. The coronary microvasculature is the primary blood supply to meet 
the metabolic needs of the myocardium.6 Normally, the coronary vasculature dilates in 
response to stress such as physical exercise or chemicals such as acetylcholine. 
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Dysfunction of the coronary microvasculature as in CMD can lead to a mismatch in 
oxygen demand and supply resulting in ischemia. Endothelial dysfunction is the greatest 
factor driving myocardial ischemia in patients with CMD.10 Therefore, targeting 
endothelial function specifically may result in the most benefit in reducing myocardial 
ischemia in patients with CMD. 
Ischemia and inflammation caused by endothelial dysfunction can lead to 
dysfunction in nearby parenchymal cells, which in the heart results in heart failure. Heart 
failure occurs when the heart does not move blood throughout the body sufficiently.17 
Numerous articles have explored the relationship between CMD and heart failure, 
specifically heart failure with preserved ejection fraction (HFpEF). Impairments in 
endothelial function have been demonstrated in both patients with CMD and HFpEF, 
showing a common link in their pathophysiology.5,18 One study found that 75 percent of 
participants with HFpEF also had CMD.19 Another study found that impaired endothelial 
function was associated with diastolic dysfunction and increased hospitalizations for 
HFpEF.20 More research is needed to elucidate the relationship between and therapies for 
patients presenting with both CMD and HFpEF.  
Myocardial ischemia typically presents as angina. In patients with CMD, angina 
is associated with activity but does not always respond to nitroglycerine and requires 
more time to resolve than typical angina.21 Patients who present with angina usually 
receive testing via an electrocardiogram and a cardiac stress test. Generally, in patients 
with CMD these exams are positive for ischemia, but imaging does not reveal obstruction 
of the coronary arteries.6 Currently there are no techniques to directly visualize coronary 
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microcirculation.22 Therefore, CMD is diagnosed by positron emission tomography. The 
patient is given a vasodilatory agent such as adenosine and coronary flow is assessed. 
Coronary flow reserve (CFR) is a marker of the capacity of coronary artery 
vasodilation and resulting enhancement of blood flow. CFR is a calculation of the ratio of 
myocardial blood flow in a hyperemic state (e.g., after administration of a vasodilating 
agent) and a resting state. CFR measures function of both large and small coronary 
vessels. CFR indicates the degree of atherosclerosis, vascular remodeling, microvascular 
and endothelial dysfunction.23 Impairment in CFR is associated with increased risk of 
adverse coronary outcomes, regardless of the degree of coronary obstruction.1,24 
Coronary artery vasodilation used to calculate CFR is measured via multiple modalities 
including intraluminal cardiac catheterization, positron emission tomography, cardiac 
perfusion magnetic resonance imaging, and transthoracic doppler flow 
echocardiography.3 Position emission tomography (PET) is a functional imaging 
modality that uses a radioactive tracer to create pictures similar to an x-ray or 
computerized tomography scan. PET is a useful tool for assessing CFR because it 
provides a measure of blood flow under hyperemic conditions.25 Normal CFR values are 
generally considered 2 or greater. In CMD, there is impaired vasodilation with CFR 
typically around 0.7-0.8.26  
The presentation of angina without obstructive coronary artery disease and 
endothelial dysfunction is a common finding in women, even without typical risk factors 
for coronary artery disease.27,28 It is thought that estrogen contributes to the higher 
incidence of women than men who present with INOCA. Estrogen stimulates the 
production of nitric oxide, which promotes vasodilation. Therefore, variations in estrogen 
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throughout the menstrual cycle and after menopause affect levels of nitric oxide and 
therefore vasodilation.22 In a study performed by Taqueti et al., men were more likely to 
have obstructive coronary artery disease while women were more likely to have INOCA; 
however, there were no significant differences in baseline CFR between men and women 
suggesting there were no differences in endothelial function.23 Despite the high number 
of women with INOCA, women experienced the same number of major adverse cardiac 
events as men, especially women with impaired CFR. Men with reduced CFR also had a 
higher rate of major adverse cardiac events, although a majority of men had obstructive 
coronary artery disease.23 These findings suggest that impaired endothelial function is 
driving poor cardiovascular outcomes in both women and men.  
As with obstructive coronary artery disease, the prevention and initial 
management of CMD begins with reduction of risk factors via lifestyle modification such 
as tobacco cessation, healthy diet, and physical activity, as well as control of co-morbid 
conditions such as hypertension, dyslipidemia, and diabetes mellitus. As with most 
medical conditions, CMD has a genetic component in addition to environmental risk 
factors.29-32 One study conducted by Fedele et al. found that polymorphisms in the genes 
coding for endothelial nitric oxide synthase, subunits of the potassium-ATP channels, and 
sodium channels, were significantly correlated with CMD and ischemic heart disease. 
These findings held true even after controlling for many cardiovascular risk factors.30 Ion 
channels, such as sodium and potassium, are responsible for regulating calcium in smooth 
muscle and the endothelium. If ion channels malfunction, calcium levels dysregulate, 
which leads to endothelial dysfunction and irregular smooth muscle tone of the 
vasculature. Considering genetics is important because participants in our proposed study 
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with a genetic predisposition to CMD may not respond as well to our therapy as other 
participants without a genetic predisposition since our therapy targets the endothelium, 
not ion channels.  
 
Statement of the Problem 
Patients who present with angina and are not found to have obstructive coronary 
artery disease are usually not offered interventions such as coronary artery bypass 
grafting (CABG) or percutaneous interventions such as stenting; however, patients with 
INOCA have demonstrated significant risk for adverse cardiac events and death. INOCA  
is considered an early event in the progression of coronary artery disease as it can be 
measured before stenosis is appreciated and is somewhat reversible.33-35 Additionally, one 
study with a 10 year follow up demonstrated that 30 percent of patients with INOCA and 
CMD went on to develop obstructive coronary artery disease.3 Currently no standard 
therapy exists for the management of INOCA and CMD, despite their prevalence and 
morbidity.1,16 Therefore, even if a patient undergoes further imaging and is found to have 
CMD, providers are left to prescribe anti-anginal medications which may or may not be 
beneficial or not prescribe anything for secondary prevention of coronary artery 
disease.36,37 While there are some proposed medications, there is not enough conclusive 
research to create treatment guidelines.22 Proposed interventions include aspirin, statins, 
angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, calcium 
channel blockers, beta blockers, and pycnogenol which is a pine tree extract.6,38-45 It is 
imperative that alternative therapies are researched and developed for the many patients 
who present with INOCA and impaired endothelial function.   
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One proposed medication for the management of CMD is ticagrelor, a P2Y12 
inhibitor. Ticagrelor is currently used for its anti-platelet effects after acute coronary 
syndrome or percutaneous coronary intervention to prevent further thrombus formation 
and stenosis of the coronary arteries.46-48 As a P2Y12 inhibitor, ticagrelor interacts with 
the P2Y12 ADP-receptor on platelets. Normally, stimulation of the P2Y12 receptor on 
platelets promotes platelet activation and aggregation by decreasing the response of 
platelets to nitric oxide and increasing the production of reactive oxygen species.49 By 
blocking the P2Y12 receptor, ticagrelor inhibits this pathway and thereby decreases 
platelet activation and decreases the production of reactive oxygen species.49 These 
effects of ticagrelor are reversible, meaning that platelets resume function once ticagrelor 
is not bound to the P2Y12 receptor. This differs from medications such as aspirin which 
binds irreversibly to a different receptor on platelets, inhibiting platelets for their entire 7- 
to 10-day life cycle. Reversible binding, as with ticagrelor, allows for quicker cessation 
of anti-platelet effects if necessary, such as in the event of bleeding. Another benefit of 
ticagrelor is that it is more effective at inhibiting platelet aggregation and is associated 
with fewer acute coronary events and death than other medications in the P2Y12 inhibitor 
class such as clopidogrel.47,50 Other benefits of ticagrelor include that it does not require 
biotransformation and has a quick onset of action. Side effects of ticagrelor are usually 
minimal but may including dyspnea and bleeding. Overall, there are many benefits to the 
mechanism of action and pharmacokinetics of ticagrelor.  
Besides its anti-platelet effects, ticagrelor demonstrates a beneficial pleiotropic 
effect on endothelial function and, as such, likely would benefit patients with CMD.51,52 
Beyond platelets, P2Y12 receptors can be found on endothelial cells. One of the 
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molecules that is expressed in endothelial cells is tissue factor, a molecule that enhances 
the extrinsic coagulation pathway. Ticagrelor has been shown to decrease the expression 
of tissue factor from endothelial cells, thereby decreasing coagulation from a mechanism 
beyond platelet inhibition.49 Pleotropic effects of ticagrelor on the endothelium also affect 
vascular smooth muscle. Ticagrelor causes the endothelium to release prostacyclin and 
nitric oxide, molecules that promote vascular dilation.49 Additionally, ticagrelor inhibits 
vascular smooth muscle contraction, resulting in vasodilation, which improves blood 
flow and increases perfusion.49,53 Other P2Y12 inhibitors such as clopidogrel and 
prasugrel have not been found to have this pleotropic effect to the same extent with 
ticagrelor being associated with a significant improvement in endothelial function 
compared to clopidogrel and prasugrel in numerous studies.49,54-57  
In addition to better perfusion via beneficial effects on the endothelium, ticagrelor 
improves blood flow by increasing adenosine. Adenosine is a potent vasodilator and is a 
molecule formed by myocytes to regulate coronary blood flow, primarily at the 
microvessels.58 Higher levels of adenosine protect myocytes from stress such as ischemia 
and reperfusion injuries. Increased adenosine also relaxes the smooth muscle in blood 
vessels which increases vasodilation and decreases coronary microvascular resistance.49 
Ticagrelor increases the plasma concentration of adenosine by two mechanisms, 1) by 
inhibiting the sodium-independent equilibrative nucleoside transporter 1 which inhibits 
cellular uptake of adenosine and 2) by increasing the release of adenosine triphosphate 
(ATP) which degrades into adenosine.53  
While there is evidence to suggest ticagrelor has a beneficial effect on endothelial 
function and as such could benefit patients with CMD, the literature is limited. Existing 
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evidence of ticagrelor on microvascular and endothelial function is limited to animal 
studies, non- placebo-controlled trials, and studies with small sample sizes. Additionally, 
studies have variable patient populations with different degrees of coronary artery disease 
or other coronary artery disease risk factors. Furthermore, some studies measure the 
blood flow of peripheral vessels instead of coronary arteries.53 Currently, there are no 
randomized, placebo-controlled studies evaluating the effect of ticagrelor on endothelial 
function in the coronary vessels in patients with CMD. Our study would help elucidate a 
pharmacological therapy for CMD, a condition for which there are no conclusive 
evidence-based recommendations for pharmacologic management. Therefore, we 
propose to investigate the effects of ticagrelor versus placebo on endothelial function 
using a randomized controlled trial double-blind approach.  
 
Goals and Objectives 
 The goal of our study is to investigate the effect of a one-month trial of ticagrelor 
on CFR to determine if ticagrelor might have a use for managing patients with CMD. 
 
Hypothesis 
 We hypothesize that in patients with CMD, ticagrelor therapy, 60 mg by mouth 
twice daily for one month, compared to placebo, will be associated with a statistically 





Non-obstructive coronary artery disease or ischemia with no obstructive coronary artery 
disease (INOCA): variable definitions, but generally considered stenosis less than 50 
percent in one or more coronary arteries.  
Coronary microvascular dysfunction (CMD): Improper functioning of the coronary 
vessels primarily driven by endothelial dysfunction. CMD is diagnosed via impaired 
coronary flow reserve.  
Endothelial dysfunction: Improper functioning of the endothelium, the lining of blood 
vessels. Endothelial dysfunction heavily contributes to microvascular dysfunction. 
Coronary flow reserve (CFR): Coronary flow reserve is a marker of endothelial function 
and is used to diagnose coronary microvascular dysfunction. CFR is a calculated from the 
ratio of myocardial blood flow in a hyperemic state and a resting state. CFR can be 
measured via intraluminal cardiac catheterization, positron emission tomography, cardiac 
perfusion magnetic resonance imaging, and transthoracic doppler flow echocardiography. 
Normal CFR is generally regarded as a value of 2 or greater.  
Ticagrelor: A medication that inhibits the P2Y12 receptor found on platelets, working to 
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Chapter 2 – Review of the Literature  
 
Introduction  
 A systematic review of the literature was performed during December 2018. 
PubMed, Scopus, and Cochrane were searched. Search terms can be found in the 
Appendix. Results were filtered for the English language. No other filters were applied in 
order to capture all types of literature. PubMed resulted in seven articles, four of which 
were relevant to the topic upon abstract review. Cochrane did not result in any relevant 
review articles. Scopus revealed one relevant article. The remainder of the literature 
search was completed via hand review.  
 
Review of studies regarding ticagrelor and endothelial function 
Ticagrelor has been proposed to improve endothelial function and, as such, may 
benefit patients with CMD since CMD is primarily driven by endothelial dysfunction.1 
While there have been no randomized controlled trials examining the effects of ticagrelor 
versus placebo on the endothelium of coronary vessels in patients with CMD, there have 
been numerous studies investigating the effects of ticagrelor on peripheral endothelial 
function in varying populations including animal models, healthy participants, and those 
with a history of acute coronary syndrome.  
Ganbaatar, et al. examined the effects of ticagrelor in an animal model.2 The study 
utilized a male mouse that is genetically bred to function as a model of atherosclerosis 
and hypercholesterolemia. The mice were fed chow resembling a Western diet alone or 
mixed with ticagrelor for 20 days. The primary outcome was vasodilation induced by 
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acetylcholine assessed in the descending thoracic aorta after the mice were sacrificed. 
Mice fed ticagrelor had less impaired vasodilation than mice fed chow without 
medication, suggesting that ticagrelor improved blood flow. One limitation to the study is 
potential variability in plasma levels of ticagrelor among the mice in the intervention 
group as serum ticagrelor levels were not measured. Another limitation of the study is 
that vasodilation was assessed after the mice had been sacrificed, not in vivo. While the 
mice were bred to have risk factors of coronary artery disease and as such may reflect our 
study population, the main limitation to the study is that it used an animal model, which 
limits the generalizability to humans.2  
Gao et al. investigated ticagrelor in humans using a laboratory marker of 
endothelial function as one of the primary outcome measures.3 The study was conducted 
as a randomized controlled trial. A total of 193 participants who were admitted to the 
hospital with ST-elevation myocardial infarction and underwent emergent percutaneous 
intervention were recruited. Patients were randomized to treatment with ticagrelor or 
clopidogrel. Primary outcome measures consisted of laboratory values including 
endothelial cell specific molecule 1, high sensitivity C-reactive protein, and interleukin-6. 
Endothelial cell specific molecule 1 is found in plaques and is associated with 
atherosclerosis and acute coronary syndrome. Laboratory markers were drawn at 
admission and again at 24 hours, 4 days, and 7 days after admission. At time of 
admission, there were no differences in any of the laboratory values between the two 
groups. After both 4 and 7 days, all lab values decreased in each treatment group; 
however, there were significant differences between the ticagrelor and clopidogrel 
groups. Seven days after admission, levels of endothelial cell specific molecule 1 were 
17 
 
1.04+/-0.16 ng/mL among patients receiving ticagrelor and 1.11+/-0.15 ng/mL among 
patients receiving clopidogrel (p=0.002). The main strength of this study was the 
randomized controlled design, although it was not placebo controlled. Some limitations 
of this study are similar to our proposed study, such as short follow up of one month and 
recruitment from only one center. The main limitation to this study is that endothelial 
function was measured using a biomarker instead of directly measuring blood flow, 
which would better estimate the function of the endothelium. Endothelial cell specific 
molecule 1 is a marker of endothelial function and atherosclerosis; however, it is not a 
marker of the coronary vessels specifically.3 
There have been numerous studies examining the effect of ticagrelor on 
peripheral blood flow, a marker of endothelial function tested in the vessels of the 
forearms. Studies measuring peripheral blood flow vary in methodology with regards to 
population and what medications were investigated. Weisshaar et al. examined the effects 
of ticagrelor and clopidogrel on peripheral blood flow in asymptomatic, healthy 
participants.4 This was a randomized controlled trial that recruited 24 participants aged 
18 to 40 who had a body mass index of 18 to 27 and were non-smokers. The primary 
outcome was forearm blood flow measured after an initial loading dose of the assigned 
medication and after 14 days of maintenance dosing. Additionally, forearm blood flow 
was measured before and after 20 minutes of ischemia to the forearm induced with a 
pneumatic cuff. Forearm blood flow after 14 days of treatment for participants receiving 
ticagrelor was 0.86 (0.71; 1.00) and was 0.66 (0.55; 0.77) for participants receiving 
clopidogrel (p=0.027). These results indicate that after two weeks of therapy, ticagrelor 
was superior to clopidogrel at improving forearm blood flow. The main limitation to this 
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study is that it recruited asymptomatic healthy volunteers, not patients with angina or 
coronary artery disease. Another limitation to the study is that it was single-blinded with 
only the clinicians being blinded, not the participants.4  
Van Den Berg et al. also recruited asymptomatic, healthy participants and 
measured forearm blood flow.5 However, instead of comparing ticagrelor to another 
P2Y12 inhibitor, they tested ticagrelor against placebo. They conducted the study using a 
cross-over design that was double-blind and placebo controlled. The study involved 14 
males who were healthy non-smokers without coronary artery disease. Forearm 
vasodilation induced by adenosine was measured two hours after ticagrelor was given. 
The study did not reveal any statistically significant differences in forearm vasodilation 
between participants receiving ticagrelor or placebo. Forearm blood flow was 9.0 (5.5-
17.2) mL/dL/minute in participants who received ticagrelor and 6.3 (4.9-9.2) 
mL/dL/minute in participants who received placebo (p=0.33). Strengths of the study 
methodology include comparison of ticagrelor against placebo and double blinding. The 
main limitation of the study is that blood flow was measured in the forearm, not in the 
coronary arteries. Additionally, the sample size of 14 participants is small. Furthermore, 
since the participants were healthy, it may be difficult to generalize the data of this study 
to a population with angina and CMD.5  
Torngren et al. recruited patients similar to those for our proposed study, patients 
with a history of symptomatic heart disease.6 The study examined the effects of numerous 
P2Y12 inhibitors on peripheral blood flow. They recruited 127 participants who had an 
acute coronary event within the last 3 years, but not within the last 3 months, and were 
being treated with either ticagrelor, clopidogrel, prasugrel, or no P2Y12 inhibitor for the 
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past 3 to 12 months. The primary outcome was forearm vasodilation after induced 
ischemia. Results demonstrated that there was a statistically significant improvement in 
forearm blood flow with ticagrelor in comparison to clopidogrel, prasugrel, and no 
P2Y12 inhibitor. Forearm blood flow in participants was 2.25+/-0.54 with ticagrelor, 
1.78+/-0.45 with clopidogrel, 1.64+/-0.33 with prasugrel and 1.78+/-0.53 with no P2Y12 
inhibitor resulting in p values less than 0.01 for ticagrelor against each group. As with the 
other studies, the main limitation to this study is it examines blood flow in the forearm, 
not in the coronary arteries. Another limitation is that patients were not randomized to the 
different intervention groups. As a result, there were some differences in baseline 
characteristics between the participants in each group, namely, history of ST-elevation 
myocardial infarction and coronary artery bypass grafting.6 
While these studies provide evidence to suggest that ticagrelor improves 
endothelial function, they are limited in several ways. Primarily, existing studies 
examining the effects of ticagrelor on endothelial function measure blow flow 
peripherally, not in the coronary vessels. Additionally, studies examine the effect of 
ticagrelor in healthy participants or patients with a history of an acute coronary syndrome 
event. No studies exist examining ticagrelor in patients with angina, but no obstructive 
coronary artery lesions. We aim to fill this evidence gap in the literature concerning the 





Justification of confounding variables 
 There are numerous potential confounding variables to consider for our proposed 
study. These include risk factors for coronary artery disease, conditions linked to 
microvascular dysfunction, and medications thought to affect endothelial function. Since 
our study aims to explore the relationship between ticagrelor and endothelial function, we 
need to ensure we are considering only the potential effects of ticagrelor on endothelial 
function, without our results being influenced by cardiovascular risk factors or other 
medications that may also affect endothelial function and skew our data.  
Potential confounders include risk factors for coronary artery disease such as age, 
gender, hypertension, obesity, diabetes mellitus, dyslipidemia, history of smoking, and 
family history of coronary artery disease. Age is a confounding variable because as age 
increases, endothelial cell mitochondria function decreases.7 Gender is a confounding 
variable due to the effects of estrogen on vasodilation as detailed in Chapter 1.8 
Hypertension is a confounding variable because it is known to cause microvascular 
remodeling and can therefore contribute to CMD.9,10 Obesity is a confounding variable 
due to its ability to cause systemic inflammation, which is associated with endothelial 
dysfunction. Macrophages migrate to adipose tissue and secrete cytokines that promote 
an inflammatory state.11-13 Diabetes is a confounding variable because high glucose levels 
cause dysfunction of the endothelial cell mitochondria. Additionally, high levels of 
glucose increases reactive oxygen species and nitrotyrosine formation, both of which 
harm endothelial cells.14 Finally, diabetes is associated with decreased CFR.15 
Dyslipidemia is a confounding variable because low-density lipoprotein and CFR have 
been shown to be inversely related.16,17 Current or previous tobacco use is a confounding 
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variable as smoking is associated with decreased CFR.16 Family history of coronary 
artery disease is a confounding variable because it is associated with increased risk for 
coronary artery disease.18 
Other potential confounders are conditions linked to microvascular dysfunction 
including ischemic cardiomyopathy, obstructive sleep apnea, heart failure, schizophrenia, 
dementia, peripheral neuropathy, Chagas disease, amyloidosis, chronic thromboembolic 
pulmonary hypertension, stress-related cardiomyopathy, systemic lupus erythematosus, 
cerebral vasospasm, tumor angiogenesis, no-reflow phenomenon, inflammatory bowel 
disease, hypertrophic obstructive cardiomyopathy, systemic sclerosis, and idiopathic 
cardiomyopathy.19 All of these listed conditions have been found to be associated with 
CMD, even if the pathophysiology explaining their connection is not fully elucidated.19  
Finally, additional confounders include medications thought to affect endothelial 
function. These include aspirin, statins, angiotensin converting enzyme inhibitors, 
angiotensin II receptor blockers, calcium channel blockers, beta blockers, and 
pycnogenol.1,20-28  
 
Justification of methodology  
 There were many considerations when determining our methodology. These 
considerations included study design, randomization, sampling method, inclusion criteria 
and exclusion criteria. Additionally, we considered the intervention, dosing, and 
administration of the intervention medication. Furthermore, we considered the control 
group and how to measure adherence.  Finally, we considered what data to collect 
including primary and secondary outcomes, and how to obtain and categorize these data. 
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We considered two randomization methods. One option is to randomize half of 
participants to either ticagrelor or placebo for the duration of the study. Another option is 
the washout method in which each participant would be randomized to either ticagrelor 
or placebo, follow the assigned intervention, repeat imaging, then undergo a washout 
period before initiating the other intervention. An advantage to using the washout method 
is that each participant becomes his/her own control. However, the washout method 
requires more time and resources and could confound data if the washout period was not 
long enough before switching between intervention and placebo. Therefore, we decided 
to follow the method of randomizing half of participants to ticagrelor or placebo for the 
duration of the study. Randomization will be done using a randomization software, 
assigning participants to ticagrelor or placebo in a 1:1 fashion while blocking for age and 
gender to better minimize the likelihood of difference between the two treatment groups. 
The sampling method will be consecutive quota sampling as this method better controls 
for sampling bias.  
Inclusion criteria consists of patients found to have CMD diagnosed via PET at 
Yale New Haven Hospital. We are recruiting patients who already received testing via 
PET in order to maintain consistency as we will be repeating a PET scan after one month 
of therapy. Additionally, patients invited to participate must be aged 18 to 65. An adult 
age range was chosen to exclude the pediatric population and geriatric participants. 
Pediatric participants are excluded as children are unlikely to carry a diagnosis of CMD 
and there are numerous ethical considers when conducting research with a pediatric 
population. Geriatric participants are excluded as increased age is associated with 
increased incidence of endothelial dysfunction and as such could confound our data.7 
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When determining exclusion criteria, we considered our study population of 
interest, other diseases that affect endothelial function, as well as safety considerations 
and contraindications to administering ticagrelor. More details regarding exclusion 
criteria can be found in Chapter 3 as well as Table 2. Patients with obstructive coronary 
artery disease will be excluded as we are particularly interested in patients with INOCA 
and CMD. Patients with heart failure, high triglycerides, and diabetes mellitus will be 
excluded as these conditions are known to affect endothelial function.14,15,20,29  
Patients on dialysis and patients with moderate to severe liver disease will be 
excluded because ticagrelor has not been studied in these populations and therefore, its 
safety in these populations is not known.30 Additionally, any patient with a history of 
intracranial hemorrhage, active bleeding such as a peptic ulcer, history of sick sinus 
syndrome or second or third degree atrioventricular block not protected by a pacemaker, 
and patients with a hypersensitivity to ticagrelor will be excluded as these are a 
contraindications to using ticagrelor.30 Furthermore, patients taking medications 
associated with adverse reactions or that are contraindicated with ticagrelor will be 
excluded. These medications include flibanserin, itraconazole, lomitapide, apalutamide, 
cobimetinib, codeine, darunavir, eliglustat, fentanyl, hydromorphone, idelalisib, 
irinotecan liposomal, ivabradine, ivosidenib, morphine, naloxegol, olaparib, oxycodone, 
oxymorphone, topotecan, and venetoclax.30  
Patients with a history of an acute coronary event or percutaneous coronary 
intervention will be excluded because these patients are likely already on anti-platelet 
therapy with a P2Y12 inihibor.30 Patients on chronic anticoagulant treatment including 
ticagrelor or any other P2Y12 inhibitor and/or with a platelet count less than 75,000/mm3 
24 
 
or greater than 700,000/mm3 will be excluded due to bleeding risk. Patients taking aspirin 
at a dose greater than 100 mg per day will be excluded because ticagrelor loses its 
effectiveness at these higher doses of aspirin.30 Additionally, pregnant or breastfeeding 
patients will be excluded from the study as ticagrelor is a category C medication in 
pregnancy and has unknown effects in breastmilk. Furthermore, PET scans use 
radionucleotide markers that can be harmful to a fetus.30 Finally, patients with asthma 
will be excluded as it is contraindicated to give adenosine to patients with asthma.31 
 The two interventions of our study are ticagrelor and placebo. Ticagrelor will be 
dosed at 60 mg by mouth two times daily for one month. We chose a dose of 60 mg 
because this dose is Food and Drug Administration (FDA) approved as a maintenance 
dose used after an acute coronary event or percutaneous intervention following one year 
of a higher 90 mg dose by mouth two times daily.30 A duration of one month of therapy 
was chosen because in previous studies ticagrelor was found to have effects on peripheral 
endothelial function after just four days; therefore, we believe one month is sufficient to 
see effects on endothelial function in the coronary arteries.3 Adherence will be measured 
using the MEMS® TrackCap pill container, which records each time the cap is removed 
from the pill bottle (See Appendix).32 We chose this method because it will provide a 
more objective record of adherence than self-report.  
We will measure CFR as the primary outcome measure. Advantages to using CFR 
as the primary outcome variable are that CFR directly assesses endothelial function in the 
coronary arteries. Additionally, CFR is associated with long-term coronary outcomes. 
Furthermore, CFR can be measured non-invasively as opposed to other measures of 
coronary endothelial function such as fractional flow reserve.33,34 Fractional flow reserve 
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is the ratio of coronary artery pressure to aortic pressure during induced hyperemia, 
which requires insertion of a flow sensor in the coronary artery.34 Furthermore, fractional 
flow reserve does not assess microvascular or endothelial function as well as CFR.31 
Additionally, low CFR is more closely associated with adverse cardiovascular events 
than fractional flow reserve.34  
We will measure CFR as a continuous variable. Measuring CFR as a continuous 
variable will allow us to appreciate any significant change in CFR from baseline to one 
month after initiation of treatment. Since participants in our study will already have an 
impaired CFR before intervention, measuring CFR as a continuous variable will allow us 
to appreciate any changes in this measure with intervention. We will measure CFR as a 
continuous rather than a categorical variable. We will not measure CFR as a categorical 
variable because our proposed study is the first to examine the effects of ticagrelor on 
CFR; therefore, it may be beneficial to appreciate any small changes in CFR as measured 
as a continuous variable. If CFR were measured as a categorical variable, changes in CFR 
may not be appreciated unless they are large enough to cross the threshold of impaired to 
normal. CFR will be analyzed using the repeated measures ANOVA. The repeated 
measures ANOVA is used because the study compares a change of CFR from baseline as 
a continuous variable.  
Microvascular dysfunction can be measured in numerous ways including 
intraluminal cardiac catheterization, positron emission tomography, cardiac perfusion 
magnetic resonance imaging, and transthoracic doppler flow echocardiography.16 
Measuring CFR via intraluminal cardiac catheterization allows direct visualization of the 
coronary arteries, however it is highly invasive and carries a risk of bradycardia, coronary 
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spasm, vessel trauma, and ventricular fibrillation.31 To assess CFR using catheterization, 
a Doppler guidewire is inserted into the left anterior descending artery, which limits the 
study to only one cardiac vessel.16 Although catheterization is invasive, there have been 
some studies suggesting that non-invasive testing is not as sensitive nor specific as 
invasive testing processes to measure CFR.35  
PET can be used to assess left ventricular ejection fraction, stress-induced 
ischemia, and percent stenosis of coronary artery disease.36 Additionally, PET is 
considered the gold standard for non-invasive imaging to determine CFR as PET has 
great resolution and attenuation correction.34,37-41 Furthermore, reduced CFR as 
determined by PET is known to predict adverse cardiovascular outcomes and mortality.42 
An adverse effect of PET is exposure to radiation via the use of a radionucleotide tracer 
that is required for the imaging. 
Cardiac perfusion magnetic resonance imaging is beneficial as it does not expose 
patients to radiation, as does PET. However, it does not assess microvascular function as 
well as PET and can underestimate CFR.16,43 Additionally, imaging via cardiac perfusion 
magnetic resonance imaging can be compromised by artifact.16  
CFR can also be measured via transthoracic echocardiogram with color and pulse 
wave doppler.39 Advantages to echocardiogram is that it is less costly than all the other 
methods to measure CFR and does not expose the patient to radiation.39,44 The main 
limitation to echocardiogram is that it can only be used to measure coronary blood flow 
of the distal left anterior descending artery in order to calculate CFR.16,45 Additionally, 
findings with echocardiogram are not always in concordance with PET findings.40 
Furthermore, transthoracic echocardiograms are limited by increased soft tissue as in 
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obesity, which may be prevalent in the patient population with CMD as obesity is 
associated with endothelial dysfunction. 
We will measure several secondary outcomes including coronary events, quality 
of life, and adverse effects of ticagrelor. The coronary events we will measure include 
myocardial ischemia, hospitalizations due to angina or heart failure, and mortality. We 
are measuring coronary events as secondary outcomes because patients with CMD are at 
risk for these events, but these events are unlikely to happen with enough frequency 
within one month to reach statistical significance to be measured as primary outcomes. 
We will measure adverse effects of ticagrelor as secondary outcomes. It is important to 
consider adverse effects of ticagrelor as side effects may affect patient adherence to 
therapy. Adverse effects of ticagrelor include bleeding and dyspnea.30 Please see the 
Appendix for a sample of the questionnaire used to assess these outcomes. 
In addition to coronary events, we will measure quality of life as a secondary 
outcome. It is important to consider symptoms such as angina and how they affect quality 
of life as this is what matters most to patients, more so than endothelial function. There 
are several questionnaires available to assess quality of life in patients with coronary 
artery disease.46 We chose to utilize the Medical Outcomes Study 36-Item Short Form 
Health Survey (SF-36) to assess quality of life. The SF-36 has been utilized and validated 
in studies with participants who have experienced angina, heart failure, and myocardial 
infarction so this questionnaire is appropriate in our study as our patients will likely have 
a history of angina before presenting to our study. Additionally, the SF-36 can be 
completed in a manageable 15 minutes. The SF-36 asks 36 questions and is much shorter 
in comparison to the Sickness Impact Profile, which is another generic questionnaire used 
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to assess quality of life that consists of 136 questions.46 Please see the Appendix for a 
sample of the SF-36.  
In addition to a more general questionnaire, we will utilize the Seattle Angina 
Questionnaire-7 and the Rose Dyspnea Scale to assess for symptoms of angina and 
dyspnea that may affect quality of life in our study population. Our patients likely will 
have experienced angina before presenting to our study and may experience dyspnea as 
an adverse effect of ticagrelor. Disease-specific questionnaires are superior at detecting a 
change in quality of life and they have been validated for patients with angina, congestive 
heart failure, or after myocardial infarction. We chose these questionnaires based on the 
results of a study conducted by the International Consortium for Health Outcomes 
Measurement examining standardizing outcome measurements for patients with coronary 
artery disease.47  
The Seattle Angina Questionnaire-7 consists of seven questions regarding the 
experience of chest discomfort over the last month. It evaluates frequency, need for 
nitroglycerin, limitations to activities, limitation to enjoyment of life, and satisfaction 
with symptoms. Participants respond to questions on a qualitative graded scale consisting 
of six options. The Rose Dyspnea Scale consists of four questions. Participants are asked 
if they experience difficulty breathing while walking at different intensities. Participants 
can respond in a binary fashion, yes or no, to each of the questions. The final score ranges 
from one to four. Please see the Appendix for a sample of these questionnaires. 
Results from the questionnaires will be evaluated as a change from baseline in 
continuous variables and as such will be analyzed using repeated measures ANOVA. 
Questionnaire responses will be evaluated as continuous variables to assess for change 
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from baseline after therapy as certain symptoms may be present both before and after 
intervention but may improve in severity. Furthermore, we will measure adverse cardiac 
events including acute coronary syndrome, hospitalizations due to angina or heart failure, 
and mortality. Adverse outcomes will be assessed as categorical variables and will be 
analyzed using Chi Square test. Additionally, we will measure side effects of ticagrelor 
including bleeding. Bleeding will be evaluated as a categorical variable and will be 
analyzed using the Chi Square test. Adverse cardiac events and adverse outcomes to 
ticagrelor will be analyzed as categorical variables because they are binary outcomes, 
either occurring or not. 
 
Conclusion 
Existing literature suggests that ticagrelor has a beneficial effect on endothelial 
function, and as such, may benefit patients with CMD. To date, studies examining the 
effect of ticagrelor on endothelial function have measured endothelial function 
peripherally via forearm blood flow. No research currently exists regarding the effect of 
ticagrelor on endothelial function of the coronary vessels assessed via CFR. Additionally, 
existing literature studying the relationship between ticagrelor and endothelial function 
recruited healthy controls or patients with history of acute coronary events, not patients 
with INOCA and CMD. Our study will fill these gaps in the literature and examine the 
effect of ticagrelor on endothelial function in patients with INOCA and CMD. 
Conducting our study as a randomized, double-blind, placebo-controlled trial is beneficial 
as this method is the current gold standard of research. Additionally, our study will 
control for numerous confounding variables through our exclusion criteria and using 
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statistical analysis in order to better ensure we are isolating the effects on endothelial 
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Chapter 3 – Study Methods 
Study Design 
 We will conduct our study as a parallel, double-blind, placebo-controlled, 
randomized trial. We will randomize participants to either ticagrelor or placebo after 
recruitment and initial PET study. Participants will continue therapy for one month, then 
repeat PET imaging. Participants and study personnel will be blinded as to group 
assignment. The study coordinator will provide the intervention medication to 
participants in a container with no identifying information besides the participant’s 
Subject ID. The placebo pill will appear identical in color, size, and shape as ticagrelor.  
 
Study Population and Sampling 
We will recruit patients who undergo evaluation via PET for CMD from the Yale 
New Haven Hospital system. An informational pamphlet about our study will be 
provided to patients found to have CMD at their follow up appointment. The 
informational pamphlet will contain the study coordinator’s contact information and a 
brief description of our study. 
Inclusion criteria: Adults aged 18 to 65 years with CMD diagnosed by PET. 
Exclusion criteria: 1) Obstructive coronary artery disease defined as greater than 50 
percent stenosis in any coronary artery, 2) left ventricular ejection fraction less than 50 
percent, 3) triglycerides greater than 400 mg/dL, 4) diabetes mellitus, 5) advanced renal 
disease requiring dialysis and/or creatinine greater than 1.4 mg/dL, 6) advanced liver 
disease, 7) history of intracranial hemorrhage, 8) active bleeding such as a peptic ulcer, 9) 
history of sick sinus syndrome and/or second or third degree atrioventricular block not 
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protected by a pacemaker, 10) hypersensitivity to ticagrelor, 11) patients who 
experienced an acute coronary event within the last year including non-ST-elevation 
myocardial infarction, ST-elevation myocardial infarction, and/or percutaneous coronary 
intervention, 12) patients who are pregnant or breastfeeding, 13) patients on chronic 
anticoagulant treatment including ticagrelor or any other P2Y12 inhibitor, 14) platelet 
count less than 75,000/mm3 or greater than 700,000/mm3, 15) asthma, and 16) patients 
taking aspirin greater 100 mg per day, flibanserin, itraconazole, lomitapide, apalutamide, 
cobimetinib, codeine, darunavir, eliglustat, fentanyl, hydromorphone, idelalisib, 
irinotecan liposomal, ivabradine, ivosidenib, morphine, naloxegol, olaparib, oxycodone, 













Table 1. Inclusion and exclusion criteria  
Inclusion Criteria 
 
• Coronary microvascular dysfunction 
defined by impaired coronary flow 
reserve on PET imaging 
• Adults 18-65 years of age 
Exclusion Criteria 
 
• Obstructive coronary artery disease with 
stenosis >50% in any coronary artery 
• Left ventricular ejection fraction <50% 
• Triglycerides >400 mg/dL 
• Diabetes mellitus 
• Advanced renal disease requiring dialysis 
and/or creatinine >1.4 mg/dL 
• Advanced liver disease 
• History of intracranial hemorrhage 
• Active bleeding such as a peptic ulcer 
• History of sick sinus syndrome and/or 
second- or third-degree AV block not 
protected by a pacemaker 
• Hypersensitivity to ticagrelor 
• Acute coronary event within the last year 
including non-ST-elevation myocardial 
infarction, ST-elevation myocardial 
infarction, and percutaneous coronary 
intervention  
• Pregnant  
• Breast feeding 
• Chronic anticoagulant treatment with 
ticagrelor or any other P2Y12 inhibitor 
• Platelet count less than 75,000 or greater 
than 700,000/mm3 
• Asthma 


























Subject Protection and Confidentiality  
 We will submit the study protocol to the Yale University Institutional Review 
Board and Human Subjects Committee for approval. No study related activities will be 
conducted prior to approval. Patients interested in participating in our study will give 
written informed consent prior to enrollment. Before giving consent, we will inform 
patients of the study timeline and procedures as well as risks and benefits of participating. 
A copy of the consent form can be found in the Appendix.  
 All members of the research staff will be up to date with Health Insurance 
Portability and Accountability Act (HIPAA) privacy and security training. Protected 
patient information will require a password to access and will be stored at a workstation 
that is connected to the Yale network and equipped with appropriate security software.  
  
Recruitment, Enrollment, and Informed Consent 
We will invite patients to participate in the study at their follow up appointment 
after the patient has undergone PET and is found to have CMD. An informational 
pamphlet about our study will be provided to patients and will contain the study 
coordinator’s contact information and a brief description of our study. A copy of the 
pamphlet can be found in the Appendix. Patients will contact the study coordinator by 
phone if they are interested in participating. Recruitment will be ongoing for twenty-two 
months.  
When patients contact research staff, we will schedule patients for an initial visit 
at which time we will explain all the study procedures, risks, and potential benefits. We 
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will provide opportunities to ask questions and answer them. Patients who remain 
interested in study participation will complete informed consent. At that time, we will 
consult the patient’s electronic health record to confirm the diagnosis of CMD. We will 




We will randomize participants using a randomization software. Patients will be 
assigned to ticagrelor or placebo in a 1:1 fashion, while blocking for age and gender.  
 
Blinding and Provision of Active Agent versus Placebo 
 
Participants and study personnel will be blinded as to who is in each intervention 
group. A research pharmacy will fill MEMS® TrackCap pill containers with a one-month 
supply of ticagrelor or placebo before the study begins. Each pill container will be 
assigned a subject ID by the research pharmacy. When participants are randomized, we 
will give them a subject ID that will match a pill bottle with the correct intervention for 
their assigned intervention group. We will blind the intervention of ticagrelor or placebo 
by distributing the pills in a MEMS® pill container labelled only with the participant’s 
subject ID. Only the clinical trial pharmacist will be unblinded and will know who is 
receiving what intervention. The pharmacist will provide the filled MEMS® TrackCap 
pill containers to the study coordinator, who will distribute them to participants by 
matching the subject ID printed on the container to the participant’s assigned subject ID. 
The placebo pill will be identical in color, size, and shape as the ticagrelor pill.  
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Adherence to Treatment  
We will monitor adherence to therapy using the MEMS® TrackCap pill container. 
The MEMS® TrackCap pill container is a device with a computer chip in the spring-
loaded cap. Each time the cap is removed from the pill bottle, the computer chip records 
the date and time. Upon completing one month of therapy with either ticagrelor or 
placebo, the patient will return for a repeat PET scan. The participant will return the 
MEMS® TrackCap before the scan. Once returned, the study coordinator will download 
data from the MEMS® TrackCap. We will use adherence data for analysis.  
 
Positron Emission Tomography Methods 
 
Initial PET imaging will be conducted before enrollment in the study. Repeat PET 
imaging will be conducted after finishing one month of therapy with either ticagrelor or 
placebo. We will conduct PET imaging in a PET scanner used for clinical trials. 
Participants will refrain from caffeine and medications containing methylxanthine for 24 
hours before the scan. A scan at rest will be achieved by administrating 50 mCi rubidium-
82 over 30 seconds then acquiring images for seven minutes. We will induce stress using 
adenosine 0.14 mg/kg/minute for six minutes. Two minutes after the completion of the 
adenosine infusion, we will give another dose of 50 mCi rubidium-82 over 30 seconds to 
acquire imagines for seven minutes.1 We will monitor heart rate, blood pressure, and a 
12-lead electrocardiogram at baseline and every minute during and after the infusion of 



























Repeat positron emission 
tomography after 1 month 
Randomization of eligible 
participants 
Patients excluded 




Clinicians notify patients of study 
and invite them to participate if 
found to have coronary 
microvascular dysfunction 
Patients decline to 
participate 
Patients contact study 
coordinator if 
interested 




Study Variables and Measures 
We will collect baseline data via clinical evaluation and questionnaires. The 
clinical evaluation will include a medical history to assess for confounders and any 
exclusion criteria as previously detailed. We will administer several questionnaires upon 
enrollment in the study including the SF-36, Seattle Angina Questionnaire-7, and the 
Rose Dyspnea Scale. Participants will receive their filled MEMS® Cap pill containers 
and schedule their one-month follow up appointment at the initial research visit.  
We will assess several variables that are confounders upon enrollment into the 
study. Age is the only variable that will be operationalized as a continuous variable. 
Baseline measures that will be operationalized as categorical variables include gender, 
body mass index, blood pressure, dyslipidemia, family history of premature coronary 
artery disease, atrial fibrillation, cardiomyopathies, heart failure with preserved ejection 
fraction, history of smoking, chronic obstructive pulmonary disease, chronic 
thromboembolic pulmonary hypertension, obstructive sleep apnea, schizophrenia, 
dementia, systemic lupus erythematosus, cerebral vasospasm, tumor angiogenesis, 
inflammatory bowel disease, and use of medications including aspirin, statins, nitrates, 
angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, calcium 







Table 2. Baseline characteristics  
Characteristic Ticagrelor 
n = TBD 
Placebo 
n = TBD 
p-value 




   












HDL >50 (women) 
HDL >40 (men) 
HLD <50 (women) 
HDL <40 (men) 
Triglycerides >150 
Triglycerides <150 
   
Family history of 
premature coronary 
artery disease 
   
Atrial fibrillation    
Cardiomyopathy    
Heart failure (ejection 
fraction >50%) 
   
History of smoking    
Chronic obstructive 
pulmonary artery disease 
   
Chronic thromboembolic 
pulmonary hypertension 
   
Obstructive sleep apnea    
Schizophrenia    
Dementia    
Systemic lupus 
erythematosus 
   
Cerebral vasospasm    
Tumor angiogenesis    
Inflammatory bowel 
disease 
   
Aspirin     
Statin    
Nitrate    
Angiotensin converting 
enzyme inhibitor 
   
Angiotensin II receptor 
blocker 
   
Calcium channel blocker    
Beta blocker    




The primary exposure will be active agent (ticagrelor) versus placebo. Ticagrelor 
administration will be one 60 mg tablet by mouth twice daily. The dosing of placebo will 
be identical to ticagrelor, one tablet by mouth twice daily, to maintain blinding. The 
primary outcome will be change in CFR measured by PET from enrollment in the study 
to one month follow up. CFR is calculated from myocardial blood flow (mL/min/g) at 
rest and at peak hyperemia caused by stress. Stress will be induced with an infusion of 
adenosine. We will compute myocardial blood flow using the Corridor4DM software. 
We will conduct a follow up assessment one month after randomization and 
initiation of active treatment (ticagrelor) versus placebo. Follow up assessment will 
include evaluation of secondary outcomes via repeat questionnaires. Secondary outcomes 
will include symptoms that affect quality of life as measured by questionnaires including 
the SF-36, Seattle Angina Questionnaire-7, and the Rose Dyspnea Scale. Furthermore, 
we will measure adverse cardiac events including acute coronary syndrome, 
hospitalizations due to angina or heart failure, and mortality. Additionally, we will 
measure side effects of ticagrelor including bleeding as well as dyspnea as reported with 
the Rose Dyspnea Scale. We will measure secondary outcomes at baseline and after 
completing one month of therapy.  
 
 
Sample Size Calculation 
 Currently, no study exists that examines the relationship between ticagrelor versus 
placebo on CFR as measured by PET in patients with CMD. Therefore, we will base our 
sample size calculation on a study by Baller, et al. that examined the effect of simvastatin 
on CFR as measured by PET in patients with INOCA defined as less than 30 percent 
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stenosis.2 The study by Baller, et al. was a prospective, one-arm clinical trial that 
followed 23 patients who presented with angina and had elevated cholesterol with low-
density lipoprotein greater than 150 mg/dL. After six months of therapy with simvastatin 
20 mg once daily, there was a statistically significant increase in CFR from 2.2+/-0.6 to 
2.64+/-0.6, a change of 0.44+/-0.6. We used the Power and Precision 4 software to 
calculate our sample size using the 0.44+/-0.6 change from baseline in CFR. 
 Assuming a difference of 0.44+/-0.6 in CFR in the ticagrelor versus placebo 
group, our study will require a total of 62 participants, 31 in each intervention group, to 
detect a statistically significant difference with 80% power and a 2-sided p-value of 0.05 
(See Appendix).  If the dropout rate were 30% at worst, we will need to recruit a total of 
90 participants, 45 in each intervention group, in order to achieve statistical significance.  
 
Statistical Analysis 
We will collect data on confounding variables upon enrollment in the study via 
clinical evaluation and questionnaires. Confounders will be analyzed and controlled for 
using multiple linear regression. Baseline continuous variables such as age will be given 
as medians with ranges. Student t-test will be used to evaluate differences in continuous 
variables. Baseline categorical variables will be given as percentages. These variables 
include gender, body mass index, blood pressure, dyslipidemia, family history of 
premature coronary artery disease, atrial fibrillation, cardiomyopathies, heart failure with 
preserved ejection fraction, history of smoking, chronic obstructive pulmonary disease, 
chronic thromboembolic pulmonary hypertension, obstructive sleep apnea, schizophrenia, 
dementia, systemic lupus erythematosus, cerebral vasospasm, tumor angiogenesis, 
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inflammatory bowel disease, and use of medications including aspirin, statins, 
angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, calcium 
channel blockers, beta blockers, and pycnogenol. Chi Square test will be used to evaluate 
differences in categorical variables.  
 The main outcome of CFR will be evaluated as a change from baseline in a 
continuous variable with a mean and standard deviation. Therefore, CFR will be analyzed 
using repeated measures ANOVA. Secondary outcomes will include results from 
questionnaires including the SF-36, Seattle Angina Questionnaire-7, and the Rose 
Dyspnea Scale. Results from questionnaires will be evaluated as a change from baseline 
in continuous variables and as such will be analyzed using repeated measures ANOVA. 
Furthermore, we will measure adverse cardiac events including acute coronary syndrome, 
hospitalizations due to angina or heart failure, and mortality. Adverse outcomes will be 
assessed as categorical variables and will be analyzed using Chi Square test. 
Additionally, we will measure side effects of ticagrelor including bleeding and dyspnea. 
Bleeding and dyspnea will be evaluated as categorical variables and will be analyzed 
using Chi Square test. 
 
Timeline and Resources 
 If the study is approved by the Yale University Institutional Review Board and 
Human Subjects Committee, recruitment will begin January 2020. Enrollment will be 
ongoing between January 2020 and November 2021 for a total of twenty-two months. We 
will collect data between January 2020 and January 2022. Data collection will consist of 
an initial clinical evaluation with questionnaire administration as well as a repeat PET 
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study and questionnaire administration one month after initiating treatment. Staffing 
requirements will include a study coordinator who will oversee the project. The study 
coordinator will be a clinician such as a physician assistant or nurse practitioner who is 
able to conduct a clinical exam to acquire medical history and administer questionnaires 
upon enrollment and after one month of therapy. Study personnel will also include a 
diagnostic cardiologist who will perform and interpret the repeat PET study. 
Furthermore, we will need a pharmacist from the clinical trial pharmacy to package 
ticagrelor or placebo for each participant. Finally, we will need a statistician to perform 
data entry and analysis. Analysis and preparation for publication will be ongoing between 
January through December 2022. We will aspire for publication in January 2023.  
Our research study will require access to a PET scanner used for clinical trials. 
Additionally, our clinicians will need rooms to conduct clinical evaluations and 
administer questionnaires. Finally, the study coordinator and statistician will require a 
workstation that is connected to the Yale network and equipped with the appropriate 
security software for analysis and storage of the study data.  
Funding will be required in order to cover the cost of compensation for 
participants. The initial and repeat exams with our study clinician will last about one hour 
each and will compensate $20 for each visit for a total of $40. The repeat PET scan will 
last about one hour and will compensate $100. If participants return the MEMS® 
TrackCap, they will receive the full $10 bonus for completing the study. If participants do 
not return the MEMS® TrackCap, they will only receive a $5 bonus for completing the 
study. In total, by completing the entire study, participants have an opportunity to receive 
$150. In addition to compensation for their time, we will compensate for any cost 
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participants incur during the study. Costs include parking fees, bus passes, gas mileage, 
and tolls. All clinic visits, imaging, and medications will be covered by our study in full. 
There will be no out-of-pocket medical costs. If we recruit 90 participants, our minimal 
cost for compensating participants will be $13,500. 
Additionally, we will require funding for a one-month supply of ticagrelor or 
placebo for all participants. If we recruit 90 participants, there will be 45 participants in 
each group. Both the ticagrelor and placebo group will receive twice daily dosing for 30 
days. Therefore, the study will require a total of 2,700 placebo tablets and 2,700 
ticagrelor 60 mg tablets. One 60 mg tablet of ticagrelor costs $7.06. The total cost of 
ticagrelor tablets will be $19,062. 
We will require funding for a full-time study coordinator, access and use of a PET 
scanner, diagnostic radiologists time for conducting and interpreting PET studies, 
clinician time for clinical evaluation and administrating questionnaires to participants at 
enrollment and after one month of therapy, pharmacy contract, MEMS® TrackCap for all 
participants (90 MEMS® TrackCaps), statistician time for data management and analysis 
from the Yale Center for Analytical Sciences at their hourly rate, access to clinical rooms, 
and access to a secure workspace for analysis and storage of study data. We have not yet 
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Chapter 4 – Conclusion  
 
Advantages and Disadvantages 
 There are several advantages associated with our study. Advantages include the 
study design, extensive consideration of confounding variables, and feasibility. Our study 
design is a double-blind, placebo-controlled, randomized trial, which is the current gold 
standard for research. No randomized trial exists examining the effect of ticagrelor on 
CFR in patients with CMD; therefore, our study design is unique and fills a gap in the 
literature. Furthermore, our study utilizes an extensive list of exclusion criteria to control 
for confounding variables and thereby strengthen the validity of our results. Additionally, 
our study only requires 90 participants, which makes recruitment more feasible. 
Furthermore, a smaller sample size decreases the total cost for the study, making the 
study more economically feasible. Finally, requiring only one follow up appointment 
after a short duration of therapy makes the time requirements more feasible for our 
participants, and as such, reduces the chance of loss to follow up. 
Limitations to our study include the timeline, dosing, data collection methods, and 
generalizability. One limitation of our study is the short follow-up of only one month of 
therapy, limiting the endpoints that can be considered. Long-term outcomes of coronary 
artery disease such as worsening coronary stenosis, acute coronary syndrome, heart 
failure, and mortality typically require years to be observed. While we plan to record 
hospitalizations and death as secondary outcomes, the likelihood that a participant would 
experience long-term outcomes within a one month follow up is low. To account for the 
shorter length of follow up, we will use CFR as a surrogate marker of the risk of 
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cardiovascular events. CFR is an important physiological indicator of vascular health and 
reduced CFR is associated with an increased risk of adverse cardiovascular outcomes.1,2 
While our study provides insight into the effects of ticagrelor on endothelial function, 
future studies should investigate clinical measures such as the incidence of cardiovascular 
events over a longer period than one month.   
To date, no study exists examining the dose of ticagrelor required to have a 
therapeutic effect on endothelial function. The dose of ticagrelor used in our study is the 
dose given to patients one year after non-ST-elevation acute coronary syndrome, ST-
elevation myocardial infarction, or percutaneous coronary intervention such as stent 
placement after treatment with a higher dose of 90 mg for one year.3 There is no 
suggested dosing of ticagrelor for patients with CMD in prevention of acute coronary 
events. Lack of information about ticagrelor dosing for patients with CMD limits our 
study because we cannot be certain if our dosing is the most effective to improve 
endothelial function and thereby effect CFR. 
 Another limitation to our study is how we acquire our data. Data will be collected 
via PET imaging and questionnaires. Questionnaires rely on self-reporting, which is a 
subjective measurement. While PET is the gold standard to calculate CFR, there are 
numerous other methods. Alternative methods include intraluminal cardiac 
catheterization, cardiac perfusion magnetic resonance imaging, transthoracic doppler 
flow echocardiography, or peripheral measures of flow reserve. Using different methods 
to measure CFR hinder comparisons between studies, which may limit the ability to 
compare our data to other studies.  
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 The generalizability of our study is also limited by a lack of diversity in our 
participants with recruitment occurring only from the Yale New Haven Hospital system 
and being limited to patients age 18 to 65. While there are several Yale New Haven 
Hospital affiliated locations, recruiting from only one hospital system makes our data less 
generalizable to the overall population of patients with CMD. An upper age limit of 65 
years excludes older adults who may otherwise qualify to participate in our study; 
however, older patients are excluded because endothelial function declines with age and 
therefore increased age may confound our results, as we are measuring CFR, a measure 
of endothelial function.  
Finally, the generalizability of our study is limited due to numerous exclusion 
criteria. The exclusion criteria are quite extensive in order to better control for 
confounding variables. However, excluding so many participants decreases the 
generalizability of the study results to the greater population with CMD. For example, 
patients with heart failure are excluded from our study, but several studies within the past 
few years have demonstrated a relationship between CMD and heart failure. Overall, 
these components of our study design decrease the diversity of our study population and 




Investigators should further elucidate clinical outcomes of ticagrelor in patients 
with CMD such as trials with longer follow up and dosing studies of ticagrelor on clinical 
outcomes. Furthermore, future studies should investigate more details as to how 
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ticagrelor affects endothelial function. Studies can determine the onset of when ticagrelor 
impacts endothelial function, the therapeutic dose of ticagrelor to influence endothelial 
function, and how long ticagrelor affects endothelial function.4 Finally, investigators can 
explore the synergistic effects of ticagrelor and other proposed medications with effects 
on endothelial function in patients with INOCA such as aspirin, statins, angiotensin 
converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, 
beta blockers, and pycnogenol to expand on existing knowledge of these medications and 
their relationship to INOCA. 
 Additionally, research should explore biomarkers that predict the development of 
CMD. Biomarkers are important for tracking the progression of a disease over time and 
after treatment. Biomarkers can also be used as a screening tool before further diagnostic 
imaging for CFR. While measuring CFR via PET can track endothelial function over 
time, this would expose patients to radiation. Endothelial cell specific molecule 1 has 
been proposed as a possible biomarker, but more research is needed.5 Currently, there are 
no screening guidelines for CMD.  
 Finally, future research should continue to explore the relationship between CMD 
and HFpEF. Existing studies have shown that endothelial dysfunction is present in both 
CMD and HFpEF. Therefore, similar treatment for both CMD and HFpEF likely would 




Clinical and/or Public Health Significance and Implications 
If ticagrelor was found to have a statistically significant benefit on CFR versus 
placebo, ticagrelor could function as a therapy for patients with CMD, a condition that 
currently lacks any treatment guidelines. The public health significance of therapy for 
CMD includes decreased incidence of cardiovascular morbidity and mortality. 
Furthermore, ticagrelor may improve quality of life in patients with CMD by decreasing 
symptoms of angina. Finally, better management of CMD would lead to lower health 
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Earn up to $150 for participation 
in a research study! 
 
If you have been diagnosed with 
coronary microvascular 
dysfunction by positron emission 
tomography (PET), you could 
qualify for our research study. 
 
 
Contact Sabrina Puvalowski at 
Sabrina.puvalowski@yale.edu or 
(XXX) XXX-XXXX if interested. 
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Consent for participation in a research project 
 
YALE UNIVERISTY SCHOOL OF MEDICINE – YALE NEW HAVEN HOSPITAL 
 
Study Title:  
RANDOMIZED CONTROLLED TRIAL EXAMINING TICAGRELOR VERSUS 
PLACEBO ON CORONARY FLOW RESERVE 
 
Principal Investigators: Matthew Burg, PhD; Sabrina Puvalowski, PA-S 
 
Funding Source: TBD 
 
Invitation to Participate and Description of Project 
 We are inviting you to participate in a research study that aims to examine the use 
of ticagrelor, an anti-platelet medication, to improve coronary flow reserve, a marker of 
coronary artery health. You have been asked to participate because you were found to 
have coronary microvascular dysfunction upon imaging with positron emission 
tomography (PET) and may benefit from this experimental therapy. Currently, there are 
no therapies approved by the Food and Drug Administration (FDA) for this condition. 
You will be one of about 90 participants in this study.  
Before you decide to participate in this research study, you should know potential 
risks and benefits. Our research team will go over this consent form with you and give 
you more information about our research study – what to expect, what procedures we will 
perform, any risks, and potential benefits. Once you are informed about our study, we 
will ask you if you wish to participate, and if so, you will be asked to sign this document.  
 
Description of Procedures 
 If you decide to participate in this research study, you will meet with clinicians 
from our research staff. They will ask you some questions about your past medical 
history and review any medications you may be taking. Additionally, you will fill out 
some baseline questionnaires that will ask about possible symptoms you may experience.  
 If you are eligible for this study, you will be randomly assigned to one of two 
study groups. One group will receive ticagrelor, an anti-platelet medication. The second 
group will receive a placebo pill. A placebo pill does not contain any medication but is 
designed to look the same as the ticagrelor pill. You and your clinician will not know 
which group you have been assigned to. If at any point you find out which group you are 
in, please notify one of our staff. Both groups will have a follow up appointment one 
month after starting treatment. At this follow up appointment, you will meet with a 
clinician to fill out questionnaires regarding some possible symptoms you may have 
experienced during the month of treatment. The questionnaires will ask you about chest 
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pain, difficulty breathing, and bleeding. Additionally, you will undergo another PET scan 
as you did before enrollment in the study. You will have access to these results after the 
study. You will be compensated for your time participating in this study, as well as for 
any costs you may incur during this study. These costs may include parking fees, bus 
passes, gas mileage, and tolls.  
 Information about this clinical trial will be available at 
http://www.ClinicalTrials.gov. The webpage will provide a summary about the study and 
its overall results. There will be no information on the webpage that would identify you.  
 
Risks and Inconveniences  
The most common side effects of ticagrelor include a risk of bleeding and 
shortness of breath. Shortness of breath occurs in about 14% of people and bleeding 
occurs in about 12% of people who take ticagrelor. The risk of experiencing these side 
effects is low as we will give a moderate dose of ticagrelor at 60 mg two times per day. 
Additionally, the risk of side effects is low as the duration of therapy is only one month. 
We will be asking questions about these symptoms via questionnaires at the end of the 
one month of therapy. If you experience any bleeding or intolerable shortness of breath, 
please contact your clinician and our study coordinator.  
In the case that you are being treated by a clinician who needs to know if you are 
taking an anti-platelet medication such as the P2Y12 inhibitor ticagrelor, please have 
your clinician contact our study coordinator and that information will be made available 
to him or her.  
Before enrolling in this study, you underwent a PET imaging study. PET is an 
imaging technique that uses x-rays to view the coronary arteries and measure their 
openness and blood flow. If you decide to participate in this study, you will undergo 
another PET scan after one month of therapy. PET imaging uses a radioactive tracer to 
view the blood vessels during the scan. The tracer is injected into a peripheral vein, such 
as those in the arm. The amount of radiation you are exposed to by the tracer is small. 
The United States FDA has set guidelines for the amount of safe radiation exposure from 
imaging studies such as PET. We will be following these guidelines closely.  
The primary measure we will be obtaining via the PET scan will be coronary flow 
reserve. Coronary flow reserve is a measure of blood flow in the blood vessels of the 
heart and is associated with the health of these blood vessels. If there are any new 
concerning results from the repeat PET scan, we will notify you and your clinician. The 
decision to pursue any additional tests or treatment will be determined between you and 
your clinician. Our research staff and clinicians are not responsible for any additional 
testing, examinations, or treatment based on the findings of the repeat PET scan. The 
PET images are solely for research purposes and as such, will not be available in your 





 There are no proven benefits of ticagrelor among patients with coronary 
microvascular dysfunction as this topic has yet to be studied. There is evidence to suggest 
that ticagrelor may cause a beneficial effect on the functioning of the lining of the 
coronary arteries, which may improve coronary blood flow and therefore heart health. 
Currently, there are no standard guidelines for treatment of patients with coronary 
microvascular dysfunction. While it is not probable that you will notice an improvement 
in symptoms such as angina within one month of therapy, your participation in this study 
will contribute to research that will provide us with a better understanding of potential 
future therapies for patients with coronary microvascular dysfunction.  
 
Economic Considerations 
You will be compensated for your time participating in this study. The initial and 
repeat exam with our study clinician will last about one hour each and will compensate 
$20 for each visit for a total of $40. The repeat PET scan will last about one hour and will 
compensate $100 for this visit. If you attend all the study sessions and return your issued 
pill container, you will be given a $10 bonus at your last visit. In total, by completing the 
entire study, you have an opportunity to receive $150. In addition to compensation for 
your time, we will compensate for any costs you may incur during this study. These costs 
may include parking fees, bus passes, gas mileage, and tolls. All clinic visits, imaging, 
and medications will be covered by our study in full. There will be no out-of-pocket 
medical costs.  
 
Treatment Alternatives 
 There are currently no FDA approved treatments for patients with coronary 
microvascular dysfunction.  
 
Confidentiality  
 Any identifiable information will be stored in a locked room with locked cabinets 
and any electronic medical information will require a password to access. This 
information will not be shared except with your permission or as required by United 
States federal or state law. Examples of information that is required to be reported 
includes certain infectious diseases such as tuberculosis, abuse towards children or the 
elderly, and any thoughts of hurting yourself or others. Once the study is completed and 
published, all data will be destroyed. When data from this study is published or 
discussed, no personal identifiable information will be used. 
 This study is approved by the Yale University Institutional Review Board and 
Human Subjects Committee, groups that review and monitor studies with human 
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participants. These committees will have access to our study records in the case of 
internal auditing; however, they will keep any personal information confidential.  
 
In Case of Injury 
 In the event that you become ill or injured during the course of our study, seek 
medical attention immediately and contact our study coordinator when possible. You will 
not be financially responsible for any healthcare costs related to adverse effects of our 
study such as side effects of ticagrelor or any side effect from the PET imaging. If you 
were to receive a medical bill related to the study, please contact our study coordinator. 
We will not compensate for other types of costs such as discomfort, lost wages, or 
disability. By signing this consent form, you do not give up any legal rights.  
 
Voluntary Participation and Withdrawal 
 Your participation in this research study is entirely voluntary. You are free to 
choose not to participate in this research study or withdrawal at any time without penalty. 
To withdrawal from the study, please contact our research coordinator. In this case, our 
research team will cancel any future appointments. You will be compensated for your 
time at the end of each study visit. If you decide to withdrawal from the study, you would 
not receive any monetary compensation for the parts of the study you did not complete. If 
you withdrawal from the research study, we will not collect any new health information 
about you; however, health information that we already collected may be used as data for 
our research study. Our research team may withdraw you from the study at any time if 
you no longer qualify. 
 
Questions 
 Please let anyone from our research team know if you have any questions now or 
at any point during the study. We ask you to ask any questions you may have and 











 I have read or have had this form read to me and wish to participate in this 
research study. I understand the study timeline, requirements, purpose, potential risks and 
benefits, and my ability to withdrawal from the study at any time. By signing below, I 
consent to participate in this research project and have received a copy of this consent 
form. 
 
Name of Subject:  





































































































































































































Secondary Outcomes Questionnaire  
1. Did you experience any adverse cardiac events including: 
a. Acute coronary syndrome  
i. ST-elevation myocardial infarction 
ii. Non-ST-elevation myocardial infarction 
iii. Percutaneous intervention 
b. Hospitalizations due to angina  
c. Hospitalizations due to heart failure 







[tiab] = term mentioned in the title or the abstract 
[mesh] = medical subject headings 
Coronary artery disease[mesh] OR ischemia[mesh] OR non obstructive coronary artery 
disease[tiab] OR non-obstructive coronary artery disease[tiab] OR ischemia with no 
obstructive coronary artery disease[tiab] OR INOCA[tiab] OR coronary microvascular 
disease[tiab] OR coronary microvascular dysfunction[tiab] OR endothelial 
dysfunction[tiab] OR endothelial disease 
AND 
Ticagrelor[mesh] OR brilique[tiab] OR AZD 6140[tiab] OR AZD6140[tiab] OR AZD-
6140[tiab] OR Brilinta[tiab] OR 3-(7-((2-(3,4-Difluorophenyl)cyclopropyl)amino)-5-
(propylthio)-3H-(1-3)-triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-
1,2-diol[tiab] OR P2Y12 inhibitor[tiab] OR Anti-platelet therapy[tiab] OR anti platelet 
therapy[tiab] OR Platelet Aggregation Inhibitors[tiab] OR Purinergic P2Y Receptor 
Antagonists[tiab]  
AND 
Heart[mesh] OR Endothelium[mesh] OR Positron-emission tomography[mesh] OR 
Positron emission tomography computed tomography[mesh] OR Coronary flow 
reserve[tiab] OR Endothelial function[tiab] OR Endothelial dysfunction[tiab] OR 
Microvascular function[tiab] OR Microvascular dysfunction[tiab] OR PET[tiab] OR 
PET-CT Scan[tiab] OR PET-CT Scans[tiab] OR Scan, PET-CT[tiab] OR Scans, PET-
CT[tiab] OR Positron Emission Tomography-Computed Tomography[tiab] OR 
CT PET Scan[tiab] OR CT PET Scans[tiab] OR PET Scan, CT[tiab] OR PET Scans, 
CT[tiab] OR Scan, CT PET[tiab] OR Scans, CT PET[tiab] OR CT PET[tiab] OR 
Positron Emission Tomography[tiab] OR PET Scan[tiab] OR PET Scans[tiab] OR 
Scan, PET[tiab] OR Scans, PET[tiab] OR Tomography, Positron-Emission[tiab] OR 
Tomography, Positron Emission[tiab] OR PET-CT[tiab] OR PET CT Scan[tiab] OR CT 
Scan, PET[tiab] OR CT Scans, PET[tiab] OR PET CT Scans[tiab] OR 
Scan, PET CT[tiab] OR Scans, PET CT[tiab] 
 
Cochrane: 
Coronary artery disease OR ischemia OR non obstructive coronary artery disease OR 
non-obstructive coronary artery disease OR ischemia with no obstructive coronary artery 
disease 
AND 
Ticagrelor OR brilique OR Brilinta OR anti platelet therapy OR Purinergic P2Y Receptor 
Antagonists 
AND 
Positron emission tomography computed tomography OR Coronary flow reserve OR 








Non obstructive coronary artery disease AND ticagrelor AND coronary flow reserve → 
no results 
Non obstructive coronary artery disease AND P2Y12 inhibitor AND coronary flow 
reserve → no results 
Non obstructive coronary artery disease AND Purinergic P2Y Receptor Antagonists 
AND coronary flow reserve → no results 
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